{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:26:50Z","timestamp":1781155610842,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.bone.2017.07.004","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T12:47:39Z","timestamp":1499086059000},"page":"144-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-4686","authenticated-orcid":false,"given":"L.","family":"Idolazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bertoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Antoniazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2017.07.004_bb0005","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2017.07.004_bb0010","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","article-title":"New perspectives on osteogenesis imperfecta","volume":"7","author":"Forlino","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bone.2017.07.004_bb0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s10354-015-0361-x","article-title":"Osteogenesis imperfecta: pathophysiology and treatment","volume":"165","author":"Hoyer-Kuhn","year":"2015","journal-title":"Wien. Med. Wochenschr."},{"key":"10.1016\/j.bone.2017.07.004_bb0020","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1007\/s00198-016-3723-3","article-title":"Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment","volume":"27","author":"Trejo","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2017.07.004_bb0025","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1203\/00006450-198303000-00007","article-title":"Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda","volume":"17","author":"Baron","year":"1983","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bone.2017.07.004_bb0030","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bone.2004.02.023","article-title":"Bone turnover markers in patients with osteogenesis imperfecta","volume":"34","author":"Braga","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.07.004_bb0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s002239900670","article-title":"Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters","volume":"65","author":"Cepollaro","year":"1999","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2017.07.004_bb0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/jbmr.5650100222","article-title":"Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta","volume":"10","author":"Minisola","year":"1995","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.07.004_bb0045","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/jbmr.5650090706","article-title":"Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta","volume":"9","author":"Brenner","year":"1994","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.07.004_bb0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s007740200025","article-title":"Increased bone resorption with decreased activity and increased recruitment of osteoblasts in osteogenesis imperfecta type I","volume":"20","author":"Iwamoto","year":"2002","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2017.07.004_bb0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00223-015-0061-y","article-title":"Evaluation of a modified pamidronate protocol for the treatment of osteogenesis imperfecta","volume":"98","author":"Palomo","year":"2016","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2017.07.004_bb0060","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00198-015-3216-9","article-title":"Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study","volume":"27","author":"Otaify","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2017.07.004_bb0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000369582","article-title":"The long-term effects of switching from active intravenous bisphosphonate treatment to low-dose maintenance therapy in children with osteogenesis imperfecta","volume":"83","author":"Biggin","year":"2015","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.bone.2017.07.004_bb0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40200-014-0109-y","article-title":"Bisphosphonate therapy in pediatric patients","volume":"13","author":"Eghbali-Fatourechi","year":"2014","journal-title":"J. Diabetes Metab. Disord."},{"key":"10.1016\/j.bone.2017.07.004_bb0075","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.07.004_bb0080","first-page":"251","article-title":"The growth hormone and somatomedin axis in short children with osteogenesis imperfecta","volume":"76","author":"Marini","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2017.07.004_bb0085","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1530\/EJE-10-0208","article-title":"GH in combination with bisphosphonate treatment in osteogenesis imperfecta","volume":"163","author":"Antoniazzi","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2017.07.004_bb0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/TCRM.S35788","article-title":"Clinical development of neridronate: potential for new applications","volume":"9","author":"Gatti","year":"2013","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bone.2017.07.004_bb0095","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2017.07.004_bb0100","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood.V97.5.1227","article-title":"Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta","volume":"97","author":"Horwitz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bone.2017.07.004_bb0105","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1210\/jc.2014-3072","article-title":"Effect of denosumab on the growing skeleton in osteogenesis imperfecta","volume":"99","author":"Hoyer-Kuhn","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2017.07.004_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005088.pub3","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"7","author":"Dwan","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2017.07.004_bb0115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.07.004_bb0120","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.07.004_bb0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000381713","article-title":"Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: a systematic review","volume":"84","author":"Rijks","year":"2015","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.bone.2017.07.004_bb0130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2017.07.004_bb0135","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/jbmr.5650100402","article-title":"Assessment of involutional bone loss: methodological and conceptual problems","volume":"10","author":"Adami","year":"1995","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"Suppl. 5","key":"10.1016\/j.bone.2017.07.004_bb0140","first-page":"8","article-title":"Treatment of osteogenesis imperfecta: who, why, what?","volume":"68","author":"Glorieux","year":"2007","journal-title":"Horm. Res."},{"key":"10.1016\/j.bone.2017.07.004_bb0145","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1007\/s00198-016-3531-9","article-title":"Management of patients with complex regional pain syndrome type I","volume":"27","author":"Gatti","year":"2016","journal-title":"Osteoporos. Int. J."},{"key":"10.1016\/j.bone.2017.07.004_bb0150","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","article-title":"Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta","volume":"16","author":"Devogelaer","year":"1987","journal-title":"Skelet. Radiol."},{"key":"10.1016\/j.bone.2017.07.004_bb0155","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.07.004_bb0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2016.02.015","article-title":"Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate","volume":"87","author":"Lindahl","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.07.004_bb0165","doi-asserted-by":"crossref","DOI":"10.5037\/jomr.2013.4401","article-title":"Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta","volume":"4","author":"Hennedige","year":"2013","journal-title":"J. Oral Maxillofac. Res."},{"key":"10.1016\/j.bone.2017.07.004_bb0170","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00774-011-0331-3","article-title":"Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw","volume":"30","author":"Maines","year":"2012","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2017.07.004_bb0175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11832-011-0380-0","article-title":"Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates","volume":"6","author":"Nicolaou","year":"2012","journal-title":"J. Child. Orthop."},{"key":"10.1016\/j.bone.2017.07.004_bb0180","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1517\/14740338.2016.1136287","article-title":"Safety issues and adverse reactions with osteoporosis management","volume":"15","author":"Rossini","year":"2016","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328217302302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328217302302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:42:23Z","timestamp":1757612543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328217302302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":36,"alternative-id":["S8756328217302302"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2017.07.004","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2017.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}